Fundraising FoxOphidion
Bethlehem, US · 4 known investors
Find your way into Ophidion
Sign up to see every warm intro you have to Ophidion
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Ophidion team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Ophidion is a biotechnology company developing therapeutics based on the cholinergic system and lynx gene modulators, which regulate nicotinic acetylcholine receptors. Its drug discovery programs target neurological and related conditions, including an early small-molecule smoking cessation candidate and peptide/protein programs.
Founders & leadership
JM
Julie MiwaFounderJulie Miwa is a translational neuroscientist with expertise in nicotinic receptor biology, now serving as Director and Promoter of Ophidion, an early-stage biopharmaceutical company developing gene-silencing therapeutics for neurodegenerative diseases.
YH
Yacoub HabibCEO & Chairman of the Board
BA
Brigitte AngenieuxExecutive Director of Preclinical Research
RP
Rajika PereraHead of Peptide and Protein Discovery & Development
Board
ML
Michael LarkBoard director
SF
Scott FishmanBoard director
CB
Claudine BruckBoard director
Investors · 4
__Twitter.png)
Reported raises · per SEC filings
Form D private placements$4M disclosed across 3 rounds · 2019–2024
▶$655.2KraisedOct 2024 · 8 investors · PharmaceuticalsRule 506(b)
▶$655.2KraisedOct 2024 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael LarkDirector
- Yacoub HabibExecutive Officer, Director, Promoter
- Julie MiwaDirector, Promoter
- Scott FishmanDirector
- Claudine BruckDirector
- Offering amount
- $1.2M
- Amount sold
- $655.2K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedSep 2023 · 8 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedSep 2023 · 8 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Julie MiwaDirector, Promoter
- Michael W. LarkDirector
- Scott FishmanDirector
- Claudine BruckDirector
- Yacoub HabibExecutive Officer, Promoter
- Offering amount
- $1.6M
- Amount sold
- $1.6M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.7MraisedJan 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedJan 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Yacoub HabibExecutive Officer, Promoter
- Julie MiwaDirector, Promoter
- Offering amount
- $1.7M
- Amount sold
- $1.7M
- First sale
- Oct 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 6
Esperion TherapeuticsBiopharma developing HDL-C regulating therapies; listed 2000.
Alexion PharmaceuticalsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Eli LillyEli Lilly discovers, develops, manufactures, and markets human pharmaceutical products across cardiometabolic, oncology, immunology, and neuroscience therapeutic areas, selling to healthcare providers and patients in approximately 90 countries through wholesalers, direct sales representatives, and digital platforms.
Viridian TherapeuticsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.
Maxion TherapeuticsMaxion Therapeutics develops protein and antibody therapeutics using its patented KnotBody technology, which fuses cysteine-rich miniproteins (Knottins) into antibody binding loops to target ion channels and GPCRs. It focuses on first-in-class and best-in-class treatments for diseases driven by ion channel and GPCR dysfunction, including pain, autoimmune and cardiovascular conditions.
Vividion TherapeuticsVividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins. The company operates across the full drug development spectrum from discovery to clinical development.
Companies working in the same space as Ophidion.
Frequently asked questions
- What does Ophidion do?
- Ophidion is a biotechnology company developing therapeutics based on the cholinergic system and lynx gene modulators, which regulate nicotinic acetylcholine receptors. Its drug discovery programs target neurological and related conditions, including an early small-molecule smoking cessation candidate and peptide/protein programs.
- Who founded Ophidion?
- Ophidion was founded by Julie Miwa.
- Who are Ophidion's investors?
- Ophidion's investors include Delaware Crossing Investor Group, Eisai Innovation, Inc., Gaingels, Robin Hood Ventures.
- How much funding has Ophidion raised?
- Ophidion has disclosed $4M raised across 3 rounds.
- Where is Ophidion headquartered?
- Ophidion is headquartered in Bethlehem, US.